Skip to content

Oruka Therapeutics, Inc. ORKA Common stock, shares authorized (in shares)

Common stock, shares authorized (in shares) at other companies

Amgen logo
AmgenAMGN
AbbVie logo
AbbVieABBV
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
Immunovant, Inc. logo
Immunovant, Inc.IMVT
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.03B+533%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s common stock, shares authorized (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s common stock, shares authorized (in shares)?
Oruka Therapeutics, Inc. (ORKA) reported common stock, shares authorized (in shares) of $545M in Q1 2026.
How has Oruka Therapeutics, Inc.'s common stock, shares authorized (in shares) changed year-over-year?
Oruka Therapeutics, Inc.'s common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $545M to $545M.